Barclays
AVBP icon

Barclays’s ArriVent BioPharma AVBP Stock Holding History

Barclays’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$124K Buy
+4,100
New +$126K ﹤0.01% 4213

Other funds holding AVBP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

Barclays's AVBP Position: Q3 2026 in Review

Barclays increased its ArriVent BioPharma (AVBP) stake by 16% in Q3 2026, buying an estimated $352K and bringing the position to 82,452 shares worth $2.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2446.

Barclays first reported a position in AVBP in Q1 2024 and has held it in 11 quarters since. The position peaked at $2.6M in Q4 2025. 56 funds tracked by Wall St. Rank hold AVBP as of Q3 2026.

  • Barclays held 82,452 shares of ArriVent BioPharma worth $2.5M as of Q3 2026.
  • Barclays bought 11,482 ArriVent BioPharma shares in Q3 2026, an estimated $352K.
  • ArriVent BioPharma made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #2446 holding.
  • Barclays first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 11 quarters since.
  • Barclays's ArriVent BioPharma position peaked at $2.6M in Q4 2025.
  • 56 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.